Interleukin 17A Promotes Lymphocytes Adhesion and Induces CCL2 and CXCL1 Release from Brain Endothelial Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2017 May 9

PMID 28481289

Citations 40

Authors

Dagmara Weronika Wojkowska

Piotr Szpakowski

Andrzej Glabinski

Affiliations

Soon will be listed here.

Abstract

The nature of the interaction between Th17 cells and the blood-brain barrier (BBB) is critical for the development of autoimmune inflammation in the central nervous system (CNS). Tumor necrosis factor alpha (TNF-α) or interleukin 17 (IL-17) stimulation is known to enhance the adherence of Th17 cells to the brain endothelium. The brain endothelial cells (bEnd.3) express Vascular cell adhesion molecule 1 (VCAM-1), the receptor responsible for inflammatory cell adhesion, which binds very late antigen 4 (VLA-4) on migrating effector lymphocytes at the early stage of brain inflammation. The present study examines the effect of the pro-inflammatory cytokines TNF-α and IL-17 on the adherence of Th17 cells to bEnd.3. The bEnd.3 cells were found to increase production of CCL2 and CXCL1 after stimulation by pro-inflammatory cytokines, while CCL2, CCL5, CCL20 and IL17 induced Th17 cell migration through a bEnd.3 monolayer. This observation may suggest potential therapeutic targets for the prevention of autoimmune neuroinflammation development in the CNS.

Citing Articles

Interaction between Th17 and central nervous system in multiple sclerosis.

Lai S, Wu X, Liu Y, Liu B, Wu H, Ma K Brain Behav Immun Health. 2025; 43():100928.

PMID: 39845807 PMC: 11751430. DOI: 10.1016/j.bbih.2024.100928.

Endothelial Dysfunctions in Blood-Brain Barrier Breakdown in Alzheimer's Disease: From Mechanisms to Potential Therapies.

Yue Q, Leng X, Xie N, Zhang Z, Yang D, Man Hoi M CNS Neurosci Ther. 2024; 30(11):e70079.

PMID: 39548663 PMC: 11567945. DOI: 10.1111/cns.70079.

The role of IL-17 in the pathogenesis and treatment of glioblastoma-an update on the state of the art and future perspectives.

Laszczych D, Czernicka A, Gostomczyk K, Szylberg L, Borowczak J Med Oncol. 2024; 41(8):187.

PMID: 38918274 PMC: 11199243. DOI: 10.1007/s12032-024-02434-1.

From Skin and Gut to the Brain: The Infectious Journey of the Human Commensal Fungus Malassezia and Its Neurological Consequences.

Naik B, Sasikumar J, Das S Mol Neurobiol. 2024; 62(1):533-556.

PMID: 38871941 DOI: 10.1007/s12035-024-04270-w.

Th17 Cells and IL-17A in Ischemic Stroke.

Wang J, Gao Y, Yuan Y, Wang H, Wang Z, Zhang X Mol Neurobiol. 2023; 61(4):2411-2429.

PMID: 37884768 PMC: 10973033. DOI: 10.1007/s12035-023-03723-y.

References

Antezana A, Sigal S, Herbert J, Kister I . Natalizumab-induced hepatic injury: A case report and review of literature. Mult Scler Relat Disord. 2015; 4(6):495-8. DOI: 10.1016/j.msard.2015.08.008. View

Ivan Alvarez J, Cayrol R, Prat A . Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta. 2010; 1812(2):252-64. DOI: 10.1016/j.bbadis.2010.06.017. View

Griffin G, Newton G, Tarrio M, Bu D, Maganto-Garcia E, Azcutia V . IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol. 2012; 188(12):6287-99. PMC: 3370121. DOI: 10.4049/jimmunol.1200385. View

Singh S, Zhang H, Foley J, Hedrick M, Farber J . Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol. 2007; 180(1):214-21. DOI: 10.4049/jimmunol.180.1.214. View

Schneider-Hohendorf T, Rossaint J, Mohan H, Boning D, Breuer J, Kuhlmann T . VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. J Exp Med. 2014; 211(9):1833-46. PMC: 4144733. DOI: 10.1084/jem.20140540. View

Steiner O, Coisne C, Cecchelli R, Boscacci R, Deutsch U, Engelhardt B . Differential roles for endothelial ICAM-1, ICAM-2, and VCAM-1 in shear-resistant T cell arrest, polarization, and directed crawling on blood-brain barrier endothelium. J Immunol. 2010; 185(8):4846-55. DOI: 10.4049/jimmunol.0903732. View

Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M . Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007; 13(10):1173-5. PMC: 5114125. DOI: 10.1038/nm1651. View

Carlson T, Kroenke M, Rao P, Lane T, Segal B . The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J Exp Med. 2008; 205(4):811-23. PMC: 2292221. DOI: 10.1084/jem.20072404. View

Stoler-Barak L, Barzilai S, Zauberman A, Alon R . Transendothelial migration of effector T cells across inflamed endothelial barriers does not require heparan sulfate proteoglycans. Int Immunol. 2014; 26(6):315-24. DOI: 10.1093/intimm/dxt076. View

10.

Ifergan I, Kebir H, Bernard M, Wosik K, Dodelet-Devillers A, Cayrol R . The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain. 2007; 131(Pt 3):785-99. DOI: 10.1093/brain/awm295. View

11.

Chu C, Wittmer S, Dalton D . Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J Exp Med. 2000; 192(1):123-8. PMC: 1887710. DOI: 10.1084/jem.192.1.123. View

12.

Mardiguian S, Serres S, Ladds E, Campbell S, Wilainam P, McFadyen C . Anti-IL-17A treatment reduces clinical score and VCAM-1 expression detected by in vivo magnetic resonance imaging in chronic relapsing EAE ABH mice. Am J Pathol. 2013; 182(6):2071-81. PMC: 3703548. DOI: 10.1016/j.ajpath.2013.02.029. View

13.

Gustavsson C, Agardh C, Zetterqvist A, Nilsson J, Agardh E, Gomez M . Vascular cellular adhesion molecule-1 (VCAM-1) expression in mice retinal vessels is affected by both hyperglycemia and hyperlipidemia. PLoS One. 2010; 5(9):e12699. PMC: 2938334. DOI: 10.1371/journal.pone.0012699. View

14.

Yao Y, Tsirka S . Truncation of monocyte chemoattractant protein 1 by plasmin promotes blood-brain barrier disruption. J Cell Sci. 2011; 124(Pt 9):1486-95. PMC: 3078815. DOI: 10.1242/jcs.082834. View

15.

Yao Z, Painter S, Fanslow W, Ulrich D, Macduff B, Spriggs M . Human IL-17: a novel cytokine derived from T cells. J Immunol. 1995; 155(12):5483-6. View

16.

Huppert J, Closhen D, Croxford A, White R, Kulig P, Pietrowski E . Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J. 2009; 24(4):1023-34. DOI: 10.1096/fj.09-141978. View

17.

Wojkowska D, Szpakowski P, Ksiazek-Winiarek D, Leszczynski M, Glabinski A . Interactions between neutrophils, Th17 cells, and chemokines during the initiation of experimental model of multiple sclerosis. Mediators Inflamm. 2014; 2014:590409. PMC: 3945772. DOI: 10.1155/2014/590409. View

18.

Song L, Pachter J . Monocyte chemoattractant protein-1 alters expression of tight junction-associated proteins in brain microvascular endothelial cells. Microvasc Res. 2004; 67(1):78-89. DOI: 10.1016/j.mvr.2003.07.001. View

19.

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A . Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012; 366(20):1870-80. DOI: 10.1056/NEJMoa1107829. View

20.

Sun D, Novotny M, Bulek K, Liu C, Li X, Hamilton T . Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat Immunol. 2011; 12(9):853-60. PMC: 3597344. DOI: 10.1038/ni.2081. View